DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) Q2 2019 Earnings Conference Call - Final Transcript
Feb 19, 2019 • 04:30 pm ET
Thank you for joining us this afternoon for DelMar Pharmaceuticals Shareholder Update Call and Webcast to discuss the Company's fiscal results for the second quarter of the 2019 fiscal year ending June 2019 and corporate update. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. (Operator Instructions) Please note today's call is being recorded.
Today's webcast will be accompanied by a slide presentation that can be found under the IR calendar in the Investors section of the Company's website at www.delmarpharma.com. The Company has also posted it on its home page.
At this time, I would like to remind our listeners that remarks being made during the call may state management's intentions, hopes, beliefs, expectations or predictions of the future. These are forward-looking statements that involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are based on DelMar's current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements.
Some of the factors that could cause actual results to differ materially from those contemplated by such forward-looking statements are discussed in the periodic reports DelMar Pharmaceuticals files with the Securities and Exchange Commission. These documents are available in the Investors section of the Company's website, www.delmarpharma.com and on the Securities and Exchange Commission's website. We encourage you to review these documents.
Joining me on the call from the DelMar management team are Mr. Saiid Zarrabian, President and CEO; Dr. Dennis Brown, Founder and Chief Scientific Officer; and Mr. Scott Praill, Chief Financial Officer.
It is now my pleasure to turn the call over to President and CEO, Mr. Saiid Zarrabian.
Good afternoon and thank you everyone for taking the time to join us on today's teleconference. Over the past year our efforts have been focused on running the most streamlined and efficient clinical and operational organization possible with the intention of extending our existing cash beyond expected final study results from the ongoing Phase II study at MD Anderson, as well as at least halfway through our first line GBM study being executed at Sun Yat-sen University Cancer Center in China. To achieve the above, we've been working diligently with our clinical partners to enroll and advance these important Phase II studies as quickly and as effectively as possible.
Consistent with previously stated objectives of expediting shareholder value creation, we have been executing development plans for VAL-083, our therapeutic platform by singularly focusing on the 60%-plus of GBM patients with the MGMT unmethylated status who get measurably inferior results given current approved therapies.
Our second quarter of fiscal year 2019 was extremely productive given the advancement of VAL-083's two Phase II biomarker-driven clinical trials for MGMT unmethylated glioblastoma. The first study for recurrent GBM at MD Anderson Cancer Center in Houston, Texas, and the second study is the first line GBM